Iontophoretic Application of Terbinafine Gel to the Large Toe Nail
Study Details
Study Description
Brief Summary
Terbinafine is recognized as one of the most effective drugs for the treatment of toe nail fungus (onychomycosis). This trial will be the first test of a new device to improve the delivery of terbinafine directly to the toe nail. The device uses a low level of electric current, iontophoresis, to "push" the terbinafine into the nail.
The study will involve a single application of terbinafine, in a gel form, with the iontophoretic device. The treatment will be applied to the surface of both large toenails of healthy subjects. Subjects will be asked to report any sensations in the nail or surrounding skin experienced during or after treatment. Samples from the edge of the treated toe nail will be taken at 2-4 week intervals to measure how much terbinafine was delivered to the nails, and blood samples will be taken for the first 24 hours after treatment to determine how much, if any, terbinafine was absorbed into the subjects's body. Observations will also be made of the treated toes to look for any irritation of the surrounding skin due to the treatment.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Phase 1 |
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Active Comparator: 1 Iontophoretic Dose Level 1 |
Other: Electrokinetic Transungual System (ETS) - Terbinafine Gel
Iontophoresis in conjunction with a terbinafine gel
Drug Dose: ETS drug cartridge loaded with approximately 20 mg - 35 mg of terbinafine in the gel formulation, with the load depending on the size of the toenail to be treated.
Two different drug applicators to be tested on each subject
Single treatment on each toenail; one treatment with one drug applicator design, the second treatment with the alternative drug applicator design
Iontophoretic Dose: 3 mA-min as 0.3 mA for 10 min
|
| Active Comparator: 2 Iontophoretic Dose Level 2 |
Other: ETS-Terbinafine Gel
Iontophoresis in conjunction with a terbinafine gel
Drug Dose: ETS drug cartridge loaded with approximately 20 mg - 35 mg of terbinafine in the gel formulation, with the load depending on the size of the toenail to be treated.
Two different drug applicators to be tested on each subject
Single treatment on each toenail; one treatment with one drug applicator design, the second treatment with the alternative drug applicator design
Iontophoretic Dose: 6 mA-min as 0.5 mA for 12 min
|
| Active Comparator: 3 Iontophoretic Dose Level 3 |
Other: ETS-Terbinafine Gel
Iontophoresis in conjunction with a terbinafine gel
Drug Dose: ETS drug cartridge loaded with approximately 20 mg - 35 mg of terbinafine in the gel formulation, with the load depending on the size of the toenail to be treated.
Two different drug applicators to be tested on each subject
Single treatment on each toenail; one treatment with one drug applicator design, the second treatment with the alternative drug applicator design
Iontophoretic Dose: 6 mA-min as 0.3 mA for 20 min
|
| Active Comparator: 4 Iontophoretic Dose Level 4 |
Other: ETS-Terbinafine Gel
Iontophoresis in conjunction with a terbinafine gel
Drug Dose: ETS drug cartridge loaded with approximately 20 mg - 35 mg of terbinafine in the gel formulation, with the load depending on the size of the toenail to be treated.
Two different drug applicators to be tested on each subject
Single treatment on each toenail; one treatment with one drug applicator design, the second treatment with the alternative drug applicator design
Iontophoretic Dose: 10 mA-min as 0.5 mA for 20 min
|
| Active Comparator: 5 Iontophoretic Dose Level 5 |
Other: ETS-Terbinafine Gel
Iontophoresis in conjunction with a terbinafine gel
Drug Dose: ETS drug cartridge loaded with approximately 20 mg - 35 mg of terbinafine in the gel formulation, with the load depending on the size of the toenail to be treated.
Two different drug applicators to be tested on each subject
Single treatment on each toenail; one treatment with one drug applicator design, the second treatment with the alternative drug applicator design
Iontophoretic Dose: 15 mA-min as 0.5 mA for 30 min
|
Outcome Measures
Primary Outcome Measures
- Evaluate the skin/nail sensation noted by subjects during and following iontophoretic application of terbinafine gel to the great toenail [12 weeks]
Secondary Outcome Measures
- Evaluate the uptake into the nail of the great toe and the systemic uptake and pharmacokinetics of terbinafine following a single iontophoretic application of terbinafine gel [12 weeks and 24 hours, respectively]
Eligibility Criteria
Criteria
Inclusion Criteria:
- Male and female volunteers between 18 and 75 years of age, inclusive.
Exclusion Criteria:
-
Subjects with pacemakers or automatic implantable cardioverter/defibrillator
-
Subjects with an implantable electronic device.
-
Subjects with a history of diabetes.
-
Subjects with a history of onychomycosis or an abnormal appearing nail on the great toe
-
Subject using systemic antifungal medications within 6 months prior to study enrollment.
-
Subject using prescription topical antifungal medications for toenail fungus within 3 months or other commercially available medications for toenail fungus applied directly to the toenail within 1 week prior to study enrollment.
-
Subject with a history of allergic or adverse response to terbinafine or any related anti-fungal drug
-
Participation in a previous clinical trial involving an investigational drug or device within 30 days prior to study enrollment.
-
Subject requires chronic use of analgesics, pain medication, or non-steroidal anti-inflammatory agents (NSAIDS).
-
In females of childbearing potential, a positive urine pregnancy test at screening and just prior to dosing.
-
Nursing mothers.
-
Subject with a history of alcoholism or drug abuse within the preceding 12 months.
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Cetero Research | Fargo | North Dakota | United States | 58104 |
Sponsors and Collaborators
- Transport Pharmaceuticals
Investigators
- Principal Investigator: Craig Sprenger, MD, Cetero Research, San Antonio
- Study Director: Eric M Morrel, PhD, Transport Pharmaceuticals, Inc.
- Study Director: Philip M Friden, PhD, Transport Pharmaceuticals, Inc.
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- TPI-N-111